FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1657-1664 June 5, 1997 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Multiple myeloma is a disorder in which malignant plasma cells accumulate in the bone marrow and produce an immunoglobulin, usually monoclonal IgG or IgA. Common complications of overt multiple myeloma include recurrent bacterial infections, anemia, osteolytic lesions, and renal insufficiency. Multiple myeloma is responsible for about 1 percent of all cancer-related deaths in Western countries. Its epidemiologic pattern remains obscure, and its cause is unknown.¹

Monoclonal Gammopathy of Undetermined Significance and the Natural History of Multiple Myeloma

A monoclonal gammopathy of undetermined significance is marked by the presence in the serum of monoclonal IgG or IgA without evidence of multiple myeloma. This type of gammopathy is relatively common; it occurs in about . . . [Full Text of this Article]

Clinical Features of Multiple Myeloma

The Biology of Normal and Malignant Plasma Cells

Multiple Myeloma as a Multistep Process

Interleukin-6 and the Bone Marrow Microenvironment

Therapy

Conventional-Dose Chemotherapy

High-Dose Therapy

Interferon Alfa

New Supportive Therapies

            Bisphosphonates

            Erythropoietin

Future Approaches

Source Information

From the Laboratory of Hematology, Institute of Biology (R.B.), and the Department of Clinical Oncology and Hematology (J.-L.H.), University Hospital, Nantes, France.

Address reprint requests to Dr. Bataille at the Laboratoire d'Hématologie, Institut de Biologie, 9, Quai Moncousu, 44035 Nantes CEDEX 01, France.

References

This article has been cited by other articles:

• De Bruyne, E., Bos, T. J., Asosingh, K., Vande Broek, I., Menu, E., Van Valckenborgh, E., Atadja, P., Coiteux, V., Leleu, X., Thielemans, K., Van Camp, B., Vanderkerken, K., Van Riet, I. (2008). Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival. Clin. Cancer Res. 14: 2918-2926 [Abstract] [Full Text]  
• Suvannasankha, A., Crean, C. D., Shanmugam, R., Farag, S. S., Abonour, R., Boswell, H. S., Nakshatri, H. (2008). Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide. Clin. Cancer Res. 14: 1814-1822 [Abstract] [Full Text]  
• Zhang, Y.-J., Bonaparte, R. S., Patel, D., Stein, D. A., Iversen, P. L. (2008). Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus. Molecular Cancer Therapeutics 7: 712-720 [Abstract] [Full Text]  
• Min, C.-K., Lee, M.-J., Eom, K.-S., Lee, S., Lee, J.-W., Min, W.-S., Kim, C.-C., Kim, M., Lim, J., Kim, Y., Han, K. (2007). Bortezomib in Combination with Conventional Chemotherapeutic Agents for Multiple Myeloma Compared with Bortezomib Alone. Jpn J Clin Oncol 0: hym126v1-8 [Abstract] [Full Text]  
• Carlo-Stella, C., Guidetti, A., Di Nicola, M., Lavazza, C., Cleris, L., Sia, D., Longoni, P., Milanesi, M., Magni, M., Nagy, Z., Corradini, P., Carbone, A., Formelli, F., Gianni, A. M. (2007). IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. Cancer Res. 67: 3269-3275 [Abstract] [Full Text]  
• Menoret, E., Gomez-Bougie, P., Geffroy-Luseau, A., Daniels, S., Moreau, P., Le Gouill, S., Harousseau, J.-L., Bataille, R., Amiot, M., Pellat-Deceunynck, C. (2006). Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 108: 1346-1352 [Abstract] [Full Text]  
• Dingli, D., Nowakowski, G. S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., Gastineau, D. A., Witzig, T. E., Gertz, M. A. (2006). Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood 107: 3384-3388 [Abstract] [Full Text]  
• MATSUMOTO, T., ABE, M. (2006). Bone Destruction in Multiple Myeloma. Ann. N. Y. Acad. Sci. 1068: 319-326 [Abstract] [Full Text]  
• Goodyear, O., Piper, K., Khan, N., Starczynski, J., Mahendra, P., Pratt, G., Moss, P. (2005). CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106: 4217-4224 [Abstract] [Full Text]  
• Oshima, T., Abe, M., Asano, J., Hara, T., Kitazoe, K., Sekimoto, E., Tanaka, Y., Shibata, H., Hashimoto, T., Ozaki, S., Kido, S., Inoue, D., Matsumoto, T. (2005). Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106: 3160-3165 [Abstract] [Full Text]  
• Geffroy-Luseau, A., Moreau-Aubry, A., Bataille, R., Pellat-Deceunynck, C. (2005). Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells. Int Immunol 17: 1193-1200 [Abstract] [Full Text]  
• Zhu, K., Gerbino, E., Beaupre, D. M., Mackley, P. A., Muro-Cacho, C., Beam, C., Hamilton, A. D., Lichtenheld, M. G., Kerr, W. G., Dalton, W., Alsina, M., Sebti, S. M. (2005). Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 105: 4759-4766 [Abstract] [Full Text]  
• Ma, Z., Otsuyama, K.-i., Liu, S., Abroun, S., Ishikawa, H., Tsuyama, N., Obata, M., Li, F.-J., Zheng, X., Maki, Y., Miyamoto, K., Kawano, M. M. (2005). Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 105: 3312-3318 [Abstract] [Full Text]  
• Carbone, E., Neri, P., Mesuraca, M., Fulciniti, M. T., Otsuki, T., Pende, D., Groh, V., Spies, T., Pollio, G., Cosman, D., Catalano, L., Tassone, P., Rotoli, B., Venuta, S. (2005). HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105: 251-258 [Abstract] [Full Text]  
• Descamps, G., Pellat-Deceunynck, C., Szpak, Y., Bataille, R., Robillard, N., Amiot, M. (2004). The Magnitude of Akt/Phosphatidylinositol 3'-Kinase Proliferating Signaling Is Related to CD45 Expression in Human Myeloma Cells. J. Immunol. 173: 4953-4959 [Abstract] [Full Text]  
• Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., Inoue, D., Matsumoto, T. (2004). Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484-2491 [Abstract] [Full Text]  
• Dingli, D., Peng, K.-W., Harvey, M. E., Greipp, P. R., O'Connor, M. K., Cattaneo, R., Morris, J. C., Russell, S. J. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103: 1641-1646 [Abstract] [Full Text]  
• Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J., Greipp, P. R., Kirsch, I. R., Kuehl, W. M., Hernandez, J. M., Minvielle, S., Pilarski, L. M., Shaughnessy, J. D. Jr., Stewart, A. K., Avet-Loiseau, H. (2004). Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report. Cancer Res. 64: 1546-1558 [Abstract] [Full Text]  
• Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., Crowley, J. (2004). Treatment of multiple myeloma. Blood 103: 20-32 [Abstract] [Full Text]  
• Mitsiades, C. S., Mitsiades, N. S., Bronson, R. T., Chauhan, D., Munshi, N., Treon, S. P., Maxwell, C. A., Pilarski, L., Hideshima, T., Hoffman, R. M., Anderson, K. C. (2003). Fluorescence Imaging of Multiple Myeloma Cells in a Clinically Relevant SCID/NOD in Vivo Model: Biologic and Clinical Implications. Cancer Res. 63: 6689-6696 [Abstract] [Full Text]  
• Kumar, S., Kimlinger, T. K., Lust, J. A., Donovan, K., Witzig, T. E. (2003). Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 102: 1075-1077 [Abstract] [Full Text]  
• Dingli, D., Diaz, R. M., Bergert, E. R., O'Connor, M. K., Morris, J. C., Russell, S. J. (2003). Genetically targeted radiotherapy for multiple myeloma. Blood 102: 489-496 [Abstract] [Full Text]  
• Giuliani, N., Colla, S., Lazzaretti, M., Sala, R., Roti, G., Mancini, C., Bonomini, S., Lunghi, P., Hojden, M., Genestreti, G., Svaldi, M., Coser, P., Fattori, P. P., Sammarelli, G., Gazzola, G. C., Bataille, R., Almici, C., Caramatti, C., Mangoni, L., Rizzoli, V. (2003). Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102: 638-645 [Abstract] [Full Text]  
• Giuliani, N., Caramatti, C., Roti, G., Geata, A., Colla, S., Bonomini, S., Hojden, M., La Monica, S., Sammarelli, G., Lazzaretti, M., Craviotto, L., Mangoni, L., Rizzoli, V. (2003). Hematologic Malignancies With Extramedullary Spread of Disease: Case 1. Multiple Myeloma With Extramedullary Involvement of the Pleura and Testes. JCO 21: 1887-1888 [Full Text]  
• Thompson, J. L, Hansen, L. A. (2003). Thalidomide Dosing in Patients with Relapsed or Refractory Multiple Myeloma. The Annals of Pharmacotherapy 37: 571-576 [Abstract] [Full Text]  
• Sezer, O., Heider, U., Zavrski, I., Kuhne, C. A., Hofbauer, L. C. (2003). RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2098 [Abstract] [Full Text]  
• Tharp, A. M., Woodruff, R. D., Shihabi, Z. K. (2003). IgD-Kappa Myeloma: An Unusual Case. Annals of Clinical & Laboratory Science 33: 97-100 [Abstract] [Full Text]  
• Barille-Nion, S., Barlogie, B., Bataille, R., Bergsagel, P. L., Epstein, J., Fenton, R. G., Jacobson, J., Kuehl, W. M., Shaughnessy, J., Tricot, G. (2003). Advances in Biology and Therapy of Multiple Myeloma. ASH Education Book 2003: 248-278 [Abstract] [Full Text]  
• Dingli, D., Timm, M., Russell, S. J., Witzig, T. E., Rajkumar, S. V. (2002). Promising Preclinical Activity of 2-Methoxyestradiol in Multiple Myeloma. Clin. Cancer Res. 8: 3948-3954 [Abstract] [Full Text]  
• Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., Kyle, R. A., Witzig, T. E. (2002). Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. JCO 20: 4319-4323 [Abstract] [Full Text]  
• Nabhan, C., Gajria, D., Krett, N. L., Gandhi, V., Ghias, K., Rosen, S. T. (2002). Caspase Activation Is Required for Gemcitabine Activity in Multiple Myeloma Cell Lines. Molecular Cancer Therapeutics 1: 1221-1227 [Abstract] [Full Text]  
• Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D., Matsumoto, T. (2002). Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100: 2195-2202 [Abstract] [Full Text]  
• Levinson, S. S., Elin, R. J., Yam, L. (2002). Light Chain Proteinuria and Lysozymuria in a Patient with Acute Monocytic Leukemia. Clin. Chem. 48: 1131-1132 [Full Text]  
• Xu, J L, Lai, R, Kinoshita, T, Nakashima, N, Nagasaka, T (2002). Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J. Clin. Pathol. 55: 530-534 [Abstract] [Full Text]  
• Mueller, P. S., Terrell, C. L., Gertz, M. A. (2002). Fever of Unknown Origin Caused by Multiple Myeloma: A Report of 9 Cases. Arch Intern Med 162: 1305-1309 [Abstract] [Full Text]  
• ANGELI, A., DOVIO, A., SARTORI, M. L., MASERA, R. G., CEOLONI, B., PROLO, P., RACCA, S., CHIAPPELLI, F. (2002). Interactions between Glucocorticoids and Cytokines in the Bone Microenvironment. Ann. N. Y. Acad. Sci. 966: 97-107 [Abstract] [Full Text]  
• Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., Anderson, K. C. (2002). Biologic sequelae of nuclear factor-kappa B blockade in multiple myeloma: therapeutic applications. Blood 99: 4079-4086 [Abstract] [Full Text]  
• Imrie, K., Esmail, R., Meyer, R. M., and the Members of the Hematology Disease Site Gro, (2002). The Role of High-Dose Chemotherapy and Stem-Cell Transplantation in Patients with Multiple Myeloma: A Practice Guideline of the Cancer Care Ontario Practice Guidelines Initiative. ANN INTERN MED 136: 619-629 [Abstract] [Full Text]  
• Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.-J., Harousseau, J.-L., Minvielle, S., Bataille, R. (2002). Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99: 2185-2191 [Abstract] [Full Text]  
• Badros, A., Barlogie, B., Siegel, E., Cottler-Fox, M., Zangari, M., Fassas, A., Morris, C., Anaissie, E., Van Rhee, F., Tricot, G. (2002). Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning. JCO 20: 1295-1303 [Abstract] [Full Text]  
• Silvestris, F., Cafforio, P., Tucci, M., Dammacco, F. (2002). Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 99: 1305-1313 [Abstract] [Full Text]  
• Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., Barille, S. (2001). Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533 [Abstract] [Full Text]  
• Smadja, N. V., Bastard, C., Brigaudeau, C., Leroux, D., Fruchart, C. (2001). Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98: 2229-2238 [Abstract] [Full Text]  
• Zaidi, A. A., Vesole, D. H. (2001). Multiple Myeloma: An Old Disease with New Hope for the Future. CA Cancer J Clin 51: 273-285 [Abstract] [Full Text]  
• Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., Anderson, K. C. (2001). TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804 [Abstract] [Full Text]  
• Shapiro, V. S., Mollenauer, M. N., Weiss, A. (2001). Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. Blood 98: 187-193 [Abstract] [Full Text]  
• Kawamura, C., Kizaki, M., Yamato, K., Uchida, H., Fukuchi, Y., Hattori, Y., Koseki, T., Nishihara, T., Ikeda, Y. (2000). Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 96: 2005-2011 [Abstract] [Full Text]  
• Michigami, T., Shimizu, N., Williams, P. J., Niewolna, M., Dallas, S. L., Mundy, G. R., Yoneda, T. (2000). Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha 4beta 1-integrin enhances production of osteoclast-stimulating activity. Blood 96: 1953-1960 [Abstract] [Full Text]  
• Attaelmannan, M., Levinson, S. S. (2000). Understanding and Identifying Monoclonal Gammopathies. Clin. Chem. 46: 1230-1238 [Abstract] [Full Text]  
• Rajkumar, S. V., Leong, T., Roche, P. C., Fonseca, R., Dispenzieri, A., Lacy, M. Q., Lust, J. A., Witzig, T. E., Kyle, R. A., Gertz, M. A., Greipp, P. R. (2000). Prognostic Value of Bone Marrow Angiogenesis in Multiple Myeloma. Clin. Cancer Res. 6: 3111-3116 [Abstract] [Full Text]  
• Bienzle, D., Silverstein, D. C., Chaffin, K. (2000). Multiple Myeloma in Cats: Variable Presentation with Different Immunoglobulin Isotypes in Two Cats. Vet Pathol 37: 364-369 [Abstract] [Full Text]  
• Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., Kienast, J. (2000). Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636 [Abstract] [Full Text]  
• Konigsberg, R., Zojer, N., Ackermann, J., Kromer, E., Kittler, H., Fritz, E., Kaufmann, H., Nosslinger, T., Riedl, L., Gisslinger, H., Jager, U., Simonitsch, I., Heinz, R., Ludwig, H., Huber, H., Drach, J. (2000). Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma. JCO 18: 804-804 [Abstract] [Full Text]  
• Palumbo, A., Triolo, S., Argentino, C., Bringhen, S., Dominietto, A., Rus, C., Omede, P., Tarella, C., Pileri, A., Boccadoro, M. (1999). Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients. Blood 94: 1248-1253 [Abstract] [Full Text]  
• Aoki, Y., Jaffe, E. S., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore, P. S., Tosato, G. (1999). Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. Blood 93: 4034-4043 [Abstract] [Full Text]  
• Ozaki, S., Kosaka, M., Wakahara, Y., Ozaki, Y., Tsuchiya, M., Koishihara, Y., Goto, T., Matsumoto, T. (1999). Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells. Blood 93: 3922-3930 [Abstract] [Full Text]  
• Rajkumar, S. V., Fonseca, R., Lacy, M. Q., Witzig, T. E., Therneau, T. M., Kyle, R. A., Litzow, M. R., Gertz, M. A., Greipp, P. R. (1999). Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. JCO 17: 1551-1551 [Abstract] [Full Text]  
• Kemp, C. (1999). Part four: Lung cancer, malignant melanoma, multiple myeloma. AM J HOSP PALLIAT CARE 16: 545-553 [Abstract]  
• Provan, D., O'Shaughnessy, D. F (1999). Recent advances in haematology. BMJ 318: 991-994 [Full Text]  
• Bellamy, W. T., Richter, L., Frutiger, Y., Grogan, T. M. (1999). Expression of Vascular Endothelial Growth Factor and Its Receptors in Hematopoietic Malignancies. Cancer Res. 59: 728-733 [Abstract] [Full Text]  
• Ropper, A. H., Gorson, K. C. (1998). Neuropathies Associated with Paraproteinemia. NEJM 338: 1601-1607 [Full Text]  
• Hallek, M., Leif Bergsagel, P., Anderson, K. C. (1998). Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process. Blood 91: 3-21 [Full Text]  
• Said, J. W., Rettig, M. R., Heppner, K., Vescio, R. A., Schiller, G., Ma, H. J., Belson, D., Savage, A., Shintaku, I. P., Koeffler, H. P., Asou, H., Pinkus, G., Pinkus, J., Schrage, M., Green, E., Berenson, J. R. (1997). Localization of Kaposi's Sarcoma-Associated Herpesvirus in Bone Marrow Biopsy Samples From Patients With Multiple Myeloma. Blood 90: 4278-4282 [Abstract] [Full Text]  
• Vincent, T., Jourdan, M., Sy, M.-S., Klein, B., Mechti, N. (2001). Hyaluronic Acid Induces Survival and Proliferation of Human Myeloma Cells through an Interleukin-6-mediated Pathway Involving the Phosphorylation of Retinoblastoma Protein. J. Biol. Chem. 276: 14728-14736 [Abstract] [Full Text]